These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18343783)

  • 41. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
    Lewis JT; Ketterling RP; Halling KC; Reynolds C; Jenkins RB; Visscher DW
    Am J Clin Pathol; 2005 Aug; 124(2):273-81. PubMed ID: 16040300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer.
    Savino M; Garrubba M; Parrella P; Baorda F; Copetti M; Murgo R; Zelante L; Carella M; Valori VM; Santini SA
    Clin Chim Acta; 2007 Sep; 384(1-2):52-6. PubMed ID: 17599819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ; Hyjek E; Early E; Knowles DM
    Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
    Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB
    Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
    Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
    Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays?
    Selvarajan S; Tan SY; Sii LH; Tan PH
    Pathology; 2006 Aug; 38(4):316-20. PubMed ID: 16916720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Tajiri R; Inokuchi M; Sawada-Kitamura S; Kawashima H; Nakamura R; Oyama T; Dobashi Y; Ooi A
    Pathol Int; 2014 May; 64(5):231-6. PubMed ID: 24888777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
    Seth RM; Burger AM; Kahn HJ
    Anticancer Res; 2006; 26(2A):927-31. PubMed ID: 16619488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry.
    Tabatabaeian H; Hojati Z
    Gene; 2013 Nov; 531(1):39-43. PubMed ID: 24013082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing.
    Kay E; O'Grady A; Morgan JM; Wozniak S; Jasani B
    J Clin Pathol; 2004 Nov; 57(11):1140-4. PubMed ID: 15509672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
    Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
    Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing for HER2 in breast cancer.
    Lewis F; Jackson P; Lane S; Coast G; Hanby AM
    Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
    El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
    Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma.
    Bofin AM; Ytterhus B; Martin C; O'Leary JJ; Hagmar BM
    Am J Clin Pathol; 2004 Jul; 122(1):110-9. PubMed ID: 15272539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
    Müller BM; Kronenwett R; Hennig G; Euting H; Weber K; Bohmann K; Weichert W; Altmann G; Roth C; Winzer KJ; Kristiansen G; Petry C; Dietel M; Denkert C
    Diagn Mol Pathol; 2011 Mar; 20(1):1-10. PubMed ID: 21326033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Scanning copy number and gene expression on the 18q21-qter chromosomal region by the systematic multiplex PCR and reverse transcription-PCR methods.
    Yamamoto F; Yamamoto M
    Electrophoresis; 2007 Jun; 28(12):1882-95. PubMed ID: 17523142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
    Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
    Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.